R&D | May 25, 2026
Sumitomo Pharma unveils new COURAGE & OPTYX data at AUA 2026
Highlights strong Vibegron results in older men & real-world prostate cancer insights
Highlights strong Vibegron results in older men & real-world prostate cancer insights
The findings support the continued advancement of EB-003, a first-in-class neuroplastogen designed to selectively target both 5-HT2A and 5-HT1B receptors
Clears major obesity endpoints at 80 weeks
New regulation mandates stricter prescription monitoring, sales record maintenance, and enhanced compliance across the pharmaceutical supply chain
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
The therapy is suited for patients with severe valve leakage who face elevated surgical risk due to advanced age, frailty, or multiple medical complications
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
The development comes as stroke remains one of the world’s biggest health threats
Subscribe To Our Newsletter & Stay Updated
